| Literature DB >> 33828067 |
Qiang Sun1, Siyu Liu1, Jingyi Feng1, Yue Kang1, You Zhou1, Shu Guo1.
Abstract
The directional differentiation of bone mesenchymal stem cells (BMSCs) is regulated by a variety of transcription factors and intracellular signaling pathways. In the past, it was thought that the directional differentiation of BMSCs was related to transforming growth factors, such as bone morphogenetic protein (BMP) and MAPK pathway. However, in recent years, some scholars have pointed out that the Wnt signaling pathway, which is a necessary complex network of protein interactions for biological growth and development, takes a significant role in this process and plays a major part in regulating the development of osteoblasts by exerting signal transduction into cells. Also, they have proved the Wnt protein therapeutic truly have positive effects on the viability and osteogenic capacity of bone graft. Recent studies have shown that microRNAs (miRNAs) play an important regulatory role in this process. MiRNAs such as miRNA-218, miRNA-335, miRNA-29, microRNA-30 and other miRNAs exert negative or positive effects on some crucial molecules in the Wnt/ß-catenin pathway, which in turn affect bone metabolism and osteopathy. Thus, miRNAs have been suggested as therapeutic targets for some metabolic bone diseases. This article aims to provide an update on the current status of microRNAs that target the Wnt signaling pathway in the regulation of osteogenesis and bone metabolism and includes a discussion of future areas of research, which can be a theoretical basis for bone metabolism-related diseases.Entities:
Year: 2021 PMID: 33828067 PMCID: PMC8043416 DOI: 10.12659/MSM.929510
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The role of miRNAs in osteogenesis by regulating the Wnt signaling pathway.
| MiRNAs | Relative expression | Biological function | Targets | References |
|---|---|---|---|---|
| MiR-218 | Up | Inhibit type 1 collagen generation | COL1A1 | [ |
| MiR-218 | Up | Inhibit ADAMTS2 | TIMP3 | [ |
| MiR-218 | Up | Inhibit RUNX2 | Runx2 | [ |
| MiR-218 | Up | Promote osteogenesis of MSCs | [ | |
| MiR-218 | Down | Promote osteogenesis (wnt/β-catenin pathway) | Sost | [ |
| MiR-218 | Down | Promote osteogenesis (wnt/β-catenin pathway) | Dkk2 | [ |
| MiR-218 | Down | Promote osteogenesis (wnt/β-catenin pathway) | SFRP2 | [ |
| MiR-218 | Up | Activate wnt/β-catenin pathway | β-catenin | [ |
| MiR-218 | Up | Activate wnt/β-catenin pathway | P-FZD | [ |
| MiR-218 | Up | Activate wnt signaling pathway | PPP2R5A | [ |
| MiR-335-5p | Up | Inhibit wnt/β-catenin pathway | APC | [ |
| MiR-335-5p | Up | Inhibit wnt/β-catenin pathway | AXIN-1 | [ |
| MiR-335-5p | Up | Activate wnt/β-catenin pathway | Dkk-1 | [ |
| MiR-335 | Up | Promote proliferation, migration and differentiation | GSK-3β | [ |
| MiR-335 | Up | Promote proliferation, migration and differentiation | β-catenin | [ |
| MiR-335 | Up | Promote osteogenesis | Runx2 | [ |
| MiR-335 | Up | Inhibit EMT | Twist1 | [ |
| MiR-335 | Up | Inhibit wnt/β-catenin pathway | Wnt3a,Wnt5a | [ |
| MiR-29 | Up | Promote osteogenesis | GSK-3β | [ |
| MiR-29a | Up | Inhibit wnt/β-catenin pathway | LRP6 | [ |
| MiR-29b1 | Up | Inhibit wnt/β-catenin pathway | CTNNB1 | [ |
| MiR-29 | Up | Inhibit wnt/β-catenin pathway | DKK-1 | [ |
| MiR-29 | Up | Inhibit wnt signaling pathway | KREMEN2 | [ |
| MiR-29 | Up | Inhibit wnt/β-catenin pathway | SFRP2 | [ |
| MiR-29 | Up | Inhibit wnt/β-catenin pathway | GSK-3β | [ |
| MiR-29 | Up | Inhibit wnt signaling pathway | ICAT/CTNNBIP1 | [ |
| MiR-29 | Up | Inhibit wnt signaling pathway | HBP1 | [ |
| MiR-29 | Up | Inhibit wnt signaling pathway | GLIS2 | [ |
| MiR-29 | Up | Inhibit wnt/β-catenin pathway | Wnt3a | [ |
| MiR-29 | Up | Promote osteogenesis | Osteonectin | [ |
| MiR-29-a | Up | Promote osteoblast formation | Osteonectin | [ |
| MiR-29c | Up | Promote osteoblast formation | Osteonectin | [ |
| MiR-30s | Up | Wnt/Ca2+ pathway | CamkII delta | [ |
| MiR-30c | Up | Wnt/Ca2+ pathway | CamkII delta | [ |
| MiR-30e | Up | Inhibit proliferation and migration | β-catenin | [ |
| MiR-30c | Up | Inhibit wnt/β-catenin pathway | BCL9 | [ |
| MiR-376c | Up | Inhibit wnt/β-catenin pathway | Wnt3a | [ |
| MiR-16-2-3p | Up | Inhibit wnt/Ca2+ pathway | Wnt5a | [ |
| MiR-154-5p | Up | Inhibit Planar cell Polarity pathway | Wnt11 | [ |
| MiR-139-5p | Up | Inhibit wnt signaling pathway | FZD4 | [ |
| MiR-210-3p | Up | Inhibit wnt/β-catenin pathway | LRP5 | [ |
| MiR-376c | Up | Inhibit wnt signaling pathway | ARF-GEF-1 | [ |
| MiR-139-5p | Up | Inhibit wnt signaling pathway | CTNNB1 | [ |
| MiR-210-3p | Up | activate wnt/β-catenin pathway | GSK-3β | [ |
| MiR-210-3p | Up | activate wnt/β-catenin pathway | β-catenin | [ |
| MiR-210-3p | Up | activate wnt/β-catenin pathway | TCF4 | [ |
| MiR-124 | Up | activate wnt/β-catenin pathway | GSk-3β | [ |
| MiR-135b | Up | Promote metastasis and recurrence of sarcoma | GSK-β | [ |
| MiR-135b | Up | Promote metastasis and recurrence of sarcoma | TET3 | [ |
| MiR-135b | Up | Promote metastasis and recurrence of sarcoma | CKLA | [ |
| MiR-142-3p | Up | Activate wnt/β-catenin pathway | APC | [ |
| MiR-141 | Up | Inhibit wnt/β-catenin pathway | β-catenin | [ |
| MiR-22 | Up | Inhibit wnt/β-catenin pathway | β-catenin | [ |